CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 105 enrolled
Drug / intervention
Apple Watch +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04468321
NCT04468321N/ACompleted
CompareCT.gov

Heart Watch Study: a Pragmatic Randomized Controlled Trial

Yale University·interventional·Posted Jul 13, 2020·Updated Apr 18, 2025

In Brief

A clinical study evaluating Apple Watch and Withings Move for Cardioversion and Atrial Fibrillation. Completed, enrolled 105 participants across 3 sites.

Detailed Summary

This will be a prospective multi-center, randomized, controlled trial of 150 patients conducted to assess the impact of individual use of the Apple Watch compared to the Withings Move on patient-reported and clinical outcomes at 6 months and up to 1 year.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardioversion, Atrial Fibrillation
CountriesUnited States
CollaboratorsMayo Clinic, Duke University, National Evaluation System for health Technology Coordinating Center

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJul 13, 2020
Enrollment StartAug 18, 2021
Primary CompletionDec 1, 2023
Study CompletionJun 1, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.0 years ago

Interventions

Apple Watchdevice

Participants will be assigned to the Apple Watch arm to assess the impact of individual use of the Apple Watch on patient-reported and clinical utilization outcomes using Hugo.

Withings Movedevice

Participants will be assigned to the Withings Move arm to assess the impact of individual use of the Withings Move on patient-reported and clinical utilization outcomes using Hugo.